admin – Page 3597 – Get News Story

Hepatitis B Virus (HBV) Infection Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Hepatitis B Virus (HBV) Infection Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatitis B Virus Infection Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hepatitis B Virus Infection Pipeline Outlook

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
The leading Hepatitis B Virus Infection Companies such as Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.
Promising Hepatitis B Virus Infection Pipeline Therapies such as Peginterferon Alfacon-2, Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Entecavir, Tenofovir disoproxil fumarate (TDF), Bepirovirsen and others.

Stay ahead with the most recent pipeline outlook for Hepatitis B Virus Infection. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatitis B Virus Infection Treatment Drugs

Hepatitis B Virus Infection Emerging Drugs Profile

Bepirovirsen: GSK

Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognise the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) which facilitate chronicity of the disease by helping to avoid clearance by the immune system. The ASO recruits the liver’s own enzymes to eliminate the RNA by digesting it to an inactive form. The subsequent reduction in the levels of the RNA results in a decrease in both the virus and the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the HBV DNA and antigen levels in the circulating blood. Bepirovirsen has an additional property of stimulating immune responses via Toll-like receptor 8 (TLR8) which may help the immune system to achieve durable clearance of the virus from circulating blood.

Bepirovirsen (previously known as ‘ISIS 505358 or IONIS-HBVRX’) was discovered by and jointly developed with Ionis Pharmaceuticals. Bepirovirsen is one of the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2019. Currently, the drug is in the Phase III stage of its development for the treatment of Hepatitis B Virus Infection.

VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. Currently, the drug is in the Phase II stage of its development for the treatment of Hepatitis B Virus Infection.

AB 729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase IIa randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.

AHB-137: Ausper Biopharma

AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential to be a backbone for the functional cure of CHB. In June 2023, AusperBio announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure. AHB-137’s highly potent antiviral activity in preclinical studies, along with its favorable pharmacokinetics and safety profile, garnered significant attention and recognition. Currently, the drug is in the Phase I stage of its development for the treatment of Hepatitis B Virus Infection.

The Hepatitis B Virus Infection Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis B Virus Infection with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis B Virus Infection Treatment.
Hepatitis B Virus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatitis B Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis B Virus Infection market

Explore groundbreaking therapies and clinical trials in the Hepatitis B Virus Infection Pipeline. Access DelveInsight’s detailed report now! @ New Hepatitis B Virus Infection Drugs

Hepatitis B Virus Infection Companies

Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatitis B Virus Infection Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Hepatitis B Virus Infection Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatitis B Virus Infection Market Drivers and Barriers

Scope of the Hepatitis B Virus Infection Pipeline Report

Coverage- Global
Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics and others.
Hepatitis B Virus Infection Pipeline Therapies- Peginterferon Alfacon-2, Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Entecavir, Tenofovir disoproxil fumarate (TDF), Bepirovirsen and others.
Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hepatitis B Virus Infection Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hepatitis B Virus Infection Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Hepatitis B Virus Infection: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Bepirovirsen: GSK
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
VIR 2218: Vir Biotechnology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AHB-137: Ausper Biopharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hepatitis B Virus Infection Key Companies
Hepatitis B Virus Infection Key Products
Hepatitis B Virus Infection- Unmet Needs
Hepatitis B Virus Infection- Market Drivers and Barriers
Hepatitis B Virus Infection- Future Perspectives and Conclusion
Hepatitis B Virus Infection Analyst Views
Hepatitis B Virus Infection Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus (HBV) Infection Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Solrikitug Emerges as a Promising Anti-TSLP Therapy for Severe Asthma, Poised to Address Critical Unmet Needs | DelveInsight

The major Severe Asthma companies iin the market such as AstraZeneca, Sanofi, Teva, GSK, Regeneron, Amgen, Ellodi, Bristol Myers Squibb, Revolo, EsoCap, and Pfizer, is expected to transform with the introduction of Solrikitug in the coming months.

Solrikitug (formerly known as MK-8226), developed initially by Merck & Co. and now advanced by Uniquity Bio with funding from Blackstone Life Sciences, is currently in Phase II clinical development for multiple inflammatory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and eosinophilic esophagitis. The severe asthma market, which is already dominated by major players such as AstraZeneca, Sanofi, Teva, GSK, Regeneron, Amgen, Ellodi, Bristol Myers Squibb, Revolo, EsoCap, and Pfizer, is expected to transform with the introduction of Solrikitug in the coming months.

According to DelveInsight’s comprehensive report, “Severe Asthma Market Insights, Epidemiology, and Market Forecast–2034”, the global burden of asthma remains substantial, with approximately 43 million diagnosed cases in adults and 11 million in the pediatric population across the 7MM in 2023. The United States alone accounts for about 26 million diagnosed cases. Of particular concern is severe asthma, which affects more than 5 million individuals across these markets.

Discover evolving trends in the severe asthma patient pool forecasts @ Severe Asthma Epidemiology Analysis

The severe asthma market in the 7MM is currently valued at nearly USD 8 billion and is highly competitive. Biologic therapies dominate the severe asthma treatment space, particularly those targeting type 2 inflammation pathways. Key players include AstraZeneca’s FASENRA, Sanofi and Regeneron’s DUPIXENT, and Teva’s CINQAIR. Emerging therapies like GSK’s depemokimab and AstraZeneca’s PT010 are also competing in this landscape.

Solrikitug, an anti-TSLP monoclonal antibody currently in Phase II trials, is an interesting candidate among emerging therapies for asthma and other chronic inflammatory conditions such as COPD and eosinophilic esophagitis. Originally developed by Merck & Co., it has been in-licensed by Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation.

The solrikitug mechanism of action targets TSLP, a critical epithelial cell-derived cytokine expressed in the barrier surfaces of the body, including the lungs, skin, and gut tissues. TSLP acts as a “master switch” cytokine at the top of the inflammatory cascade. By preventing TSLP from binding to its receptors, Solrikitug has the potential to disrupt multiple inflammatory pathways simultaneously, presenting a therapeutic advantage over existing biologics that target single mediators such as IL-5 or IgE.

Download the severe asthma market report to understand how Solrikitug will impact the severe asthma therapeutic market @ Severe Asthma Market Trends

It is noteworthy that tezepelumab (AstraZeneca) is the first anti-TSLP agent approved for severe asthma in 2021. However, solrikitug recognizes a different epitope compared to tezepelumab and demonstrated superior potency in preclinical studies. Solrikitug also appears to have a longer circulating half-life, which could be advantageous for patient convenience and adherence by potentially allowing for less frequent administration.

As of early 2025, several clinical trials for Solrikitug are either underway or planned to evaluate its safety, efficacy, and optimal dosing regimens across different patient populations.

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose levels, focusing on changes in blood eosinophil counts and the therapy’s safety profile. The study is estimated to be completed by August 2025.

Concurrently, the ZION Study (NCT06496620) is exploring solrikitug’s potential in COPD, the third leading cause of death worldwide, while the ALAMERE Study (NCT06598462) is investigating its efficacy in Eosinophilic Esophagitis, thereby broadening the potential applications of this promising therapy.

Additionally, a Phase I study was planned to investigate the safety, tolerability, and pharmacokinetics of Solrikitug in both Japanese and non-Japanese participants, reflecting efforts to understand potential ethnic differences in drug response. This study aims to enroll 32 participants and is scheduled to start in May 2025, with an estimated completion by December 2025.

Uniquity Bio has also indicated plans to expand its immunology and inflammation pipeline with additional programs in the near future, potentially leveraging Solrikitug as a platform for developing bispecific antibodies or combination approaches. The company’s pipeline already includes “Solrikitug-Based Bispecific 1” and “Solrikitug-Based Bispecific 2”, suggesting ongoing innovation based on this molecular platform.

The development of solrikitug represents part of a broader trend in precision medicine approaches for inflammatory conditions, where targeting specific cytokines and inflammatory mediators can potentially offer more effective and personalized treatment options, addressing significant unmet needs. The substantial investment of $300 million by Blackstone Life Sciences into Uniquity Bio underscores the significant commercial potential seen in Solrikitug.

Unlock which severe asthma drug is expected to capture the largest market share in 7MM by 2032. Visit the Severe Asthma Market Insights

Table of Contents

1	Key Insights
2	Report Introduction
3	Severe Asthma Market Overview at a Glance
4	Severe Asthma Epidemiology and Market Methodology
5	Executive Summary of Severe Asthma
6	Key Events
7	Severe Asthma Background and Overview
8	Severe Asthma Epidemiology and Patient Population
9	Severe Asthma Patient Journey
10	Severe Asthma Marketed Drugs
11	Severe Asthma Emerging Drugs
12	Severe Asthma: Seven Major Market Analysis
13	Key Opinion Leaders’ Views
14	SWOT Analysis
15	Severe Asthma Unmet Needs
16	Reimbursement and Market Access
17	Appendix
18	DelveInsight Capabilities
19	Disclaimer
20	About DelveInsight

Related Reports

Severe Asthma Pipeline Insight

Oncocytoma Pipeline Insight provides comprehensive insights about the oncocytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the oncocytoma companies including, Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, and Teva Branded Pharmaceutical Industries, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Solrikitug Emerges as a Promising Anti-TSLP Therapy for Severe Asthma, Poised to Address Critical Unmet Needs | DelveInsight

Oncocytoma Market Poised for Steady Growth by 2032, Driven by Improved Diagnostics | DelveInsight

The Oncocytoma market is experiencing notable growth, with the 7MM projected to achieve a decent CAGR, according to DelveInsight’s latest analysis. This growth reflects advancements in molecular diagnostics and minimally invasive surgical technologies that are reshaping treatment paradigms for this rare renal and salivary gland tumor.

DelveInsight’s report, “Oncocytoma – Market Insight, Epidemiology And Market Forecast – 2032”, provides a comprehensive assessment of oncocytoma market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the oncocytoma market size in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase notably over the coming years. This growth is primarily driven by the increased adoption of non-invasive treatment options and advancements in early detection technologies.

The United States represents the largest share of the oncocytoma market. The EU4 countries and the United Kingdom collectively make up the second-largest market share.

Download the oncocytoma market report to understand which factors are driving the oncocytoma therapeutic market @ Oncocytoma Market Trends

The epidemiological data presented in the report indicate key trends in incidence, demographics, and the oncocytoma patient pool. The data reveal a steadily expanding oncocytoma patient pool across the 7MM, with the median age at diagnosis for renal oncocytoma typically ranging from 62 to 68 years. Additionally, it has also been indicated that oncocytomas predominantly affect males across the studied regions.

The report also explores the current and evolving Oncocytoma treatment landscape. As of now, there are no FDA-approved drugs specifically targeting oncocytoma. Instead, oncocytomas are typically managed through surgical excision (such as partial or radical nephrectomy) or minimally invasive techniques like cryoablation or radiofrequency ablation when necessary.

While surgical intervention remains the cornerstone of current management, there is an accelerated innovation in diagnostic accuracy and the differentiation of these tumors from malignant renal counterparts. Recently, AI-driven diagnostic tools have been integrated into clinical practice, showing promising results in the diagnosis and preoperative planning for oncocytoma. One study revealed that an AI system achieved over 90% accuracy in distinguishing clear cell renal cell carcinoma (RCC) from oncocytoma using MRI scans. Additionally, a comparative analysis indicated that the AI model outperformed radiologists in distinguishing benign tumors, such as oncocytoma and angiomyolipoma, from RCC subtypes. This highlights the potential of AI to reduce diagnostic ambiguity within the oncocytoma treatment landscape.

Discover evolving trends in the oncocytoma treatment landscape @ Oncocytoma Therapeutics Market

Looking ahead, the oncocytoma market is set for significant growth, driven by advancements in diagnostic technologies and surgical techniques. Despite challenges posed by the benign nature of these tumors, which can lead to misdiagnosis and potential overtreatment, the field is witnessing a paradigm shift. The integration of artificial intelligence in imaging and the development of molecular diagnostic tools are enhancing the accuracy of preoperative diagnosis, reshaping patient management strategies

As research continues to uncover the molecular intricacies of oncocytomas, the market is expected to expand, offering more personalized treatment options and improved long-term monitoring techniques to address the unmet needs in this landscape.

Unlock which oncocytoma drug is expected to capture the largest market share in 7MM by 2032. Visit the Oncocytoma Market Insights

Table of Contents

1.	Key Insights
2.	Executive Summary of Oncocytoma
3.	Oncocytoma Competitive Intelligence Analysis
4.	Oncocytoma: Market Overview at a Glance
5.	Oncocytoma: Disease Background and Overview
6.	Oncocytoma Patient Journey
7.	Oncocytoma Epidemiology and Patient Population
8.	Oncocytoma Treatment Algorithm, Current Treatment, and Medical Practices
9.	Oncocytoma Unmet Needs
10.	Key Endpoints of Oncocytoma Treatment
11.	Oncocytoma Marketed Products
12.	Oncocytoma Emerging Therapies
13.	Oncocytoma: Seven Major Market Analysis
14.	Attribute analysis
15.	7MM: Market Outlook
16.	Oncocytoma Access and Reimbursement Overview
17.	KOL Views
18.	Oncocytoma Market Drivers
19.	Oncocytoma Market Barriers
20.	Appendix
21.	DelveInsight Capabilities
22.	Disclaimer
23.	About DelveInsight

Related Reports

Oncocytoma Pipeline Insight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oncocytoma Market Poised for Steady Growth by 2032, Driven by Improved Diagnostics | DelveInsight

Cerebral Palsy Market to Expand Significantly With a 3% CAGR Through 2034 | DelveInsight

Key Cerebral Palsy companies in the market include – Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical, are at the forefront of innovation in this field.

The Cerebral Palsy market has demonstrated substantial growth in recent years, driven by increasing awareness, improved diagnostic techniques, and the introduction of innovative therapies such as stem cell therapy, robot-assisted therapy, and constraint-induced movement therapy. Key pharmaceutical companies, including Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical, are at the forefront of innovation in this field.

DelveInsight’s report, “Cerebral Palsy Market Insights, Epidemiology, and Market Forecast – 2034“, provides a comprehensive analysis of the historical and projected market size for cerebral palsy from 2020 to 2034. The report examines various epidemiological segments and forecasts, explores market trends, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of cerebral palsy.

According to the report, the cerebral palsy market across 7MM will experience significant growth during the forecast period, with a CAGR of around 3%. This growth will be supported by the introduction of innovative therapies in the pipeline, such as MYOBLOC, UDI-001, and other treatments, coupled with advancements in genetic testing and diagnostic techniques.

Download the cerebral palsy market report to understand which factors are driving the cerebral palsy therapeutic market @ Cerebral Palsy Market Trends

The report offers a thorough epidemiological analysis and forecasts extending to 2034, segmented by total cerebral palsy prevalent cases, total diagnosed cases, and total type-specific cases within the 7MM. DelveInsight estimates approximately 2 million prevalent and 2 million diagnosed cases of cerebral palsy in these regions in 2023, with numbers anticipated to rise in the coming years.

The US accounts for the largest share of diagnosed cases, representing about 53% of total prevalent cases in the 7MM. Among the EU4 countries and the UK, the UK reported the highest number of cases, followed by Germany, while Italy recorded the lowest. It was also noted that spastic cerebral palsy is the most common form, affecting 70–80% of cases, followed by dyskinetic (15%) and ataxic (4%) types. These trends highlight the growing public health impact of cerebral palsy and the regional variations in disease burden.

The DelveInsight report also discusses current diagnosis and treatment strategies for cerebral palsy, which are multifaceted and reflect the complexity and variability of the condition. The diagnosis of cerebral palsy typically occurs within the first two years of life through developmental monitoring, imaging tests, and evaluations of motor skills and neurological function.

Treatment is highly individualized, focusing on improving motor function and quality of life. Common approaches include physical, occupational, and speech therapies to enhance mobility, daily functioning, and communication. Medications such as DYSPORT (Ipsen) and BOTOX (AbbVie), among others, are used for symptom management. In severe cases, surgical interventions may be performed to improve mobility or reduce muscle stiffness.

Despite significant advancements, existing treatment approaches face various challenges, including delayed diagnosis, a lack of evidence-based guidelines, and poorly managed transitions from pediatric to adult care. Addressing these challenges requires improved diagnostic tools, better access to multidisciplinary care, enhanced communication among stakeholders, and policies that ensure equitable healthcare services for cerebral palsy patients throughout their lifespan.

Discover evolving trends in the cerebral palsy treatment landscape @ Cerebral Palsy Therapeutics Market

DelveInsight’s analysis indicates that the current developmental pipeline for cerebral palsy treatments is highly active, with several companies initiating clinical trials for new options. Notable pipeline candidates include MYOBLOC (Supernus Pharmaceuticals), currently undergoing Phase II/III clinical trials for symptoms related to cerebral palsy in both adults and pediatric populations, and UDI-001 (Rohto Pharmaceutical) that utilizes umbilical cord-derived mesenchymal stromal cells aimed at treating cerebral palsy associated with periventricular leukomalacia, among others.

The cerebral palsy treatment landscape is witnessing significant advancements in medical technology, therapeutic interventions, diagnostic tools, and funding initiatives. Recent developments have shown promising results across various fronts, offering new hope to patients, health professionals, and researchers alike.

In January 2025, United Cerebral Palsy launched its 2025 “Change is Possible for CP” grant cycle to promote clinical and translational research. This program provides funding opportunities through multiple grant categories, assisting researchers and clinicians focusing on the early diagnosis and treatment of cerebral palsy.

Advancements in artificial intelligence are transforming research on cerebral palsy, with numerous groundbreaking studies showcasing significant progress, particularly in early detection and neuroimaging analysis. A study conducted in February 2025 introduced an AI-powered pipeline that uses automated machine learning to assess the risk of cerebral palsy by analyzing infant movements in videos. This approach achieved an ROC-AUC score of 0.78 for predicting clinical scores at 3 to 4 months of age.

Another study published in March 2025 featured a deep learning system designed to automatically quantify lesion-free brain volumes from MRI scans in children with unilateral cerebral palsy. This system successfully correlated the preservation of the thalamus with motor and visual outcomes by accurately segmenting areas of damaged brain tissue.

Unlock which cerebral palsy drug is expected to capture the largest market share in 7MM by 2032. Visit the Cerebral Palsy Market Insights

In conclusion, the cerebral palsy market is expected to experience substantial growth over the next decade, driven by innovative therapies, improved diagnostic techniques, and an active clinical development pipeline. According to the cerebral palsy market report by DelveInsight, the prevalence of cerebral palsy and the adoption of new treatments are projected to steadily increase across key markets. Robust advancements in medical technology and early detection methods are further enhancing the market’s potential and improving patient outcomes.

Table of Contents

1	Key Insights
2	Report Introduction
3	Market Overview at a Glance
4	Cerebral Palsy Epidemiology and Market Methodology
5	Cerebral Palsy Executive Summary
6	Key Events
7	Cerebral Palsy Background and Overview
8	Cerebral Palsy Diagnosis
9	Cerebral Palsy Diagnostic Guidelines
10	Cerebral Palsy Current Treatment Practices
11	Cerebral Palsy Treatment and Management Guidelines
12	Cerebral Palsy Patient Journey
13	Cerebral Palsy Epidemiology and Patient Population
14	Key Endpoints in Cerebral Palsy Clinical Trials
15	Cerebral Palsy Marketed Drugs
16	Cerebral Palsy Emerging Drugs
17	Cerebral Palsy: Market Analysis
18	Key Opinion Leaders’ Views
19	SWOT
20	Cerebral Palsy Unmet Needs
21	Market Access and Reimbursement
22	Appendix
23	DelveInsight Capabilities
24	Disclaimer
25	About DelveInsight

Spastic Cerebral Palsy Pipeline Insight provides comprehensive insights about the Spastic Cerebral Palsy pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Spastic Cerebral Palsy companies, including Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical,, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cerebral Palsy Market to Expand Significantly With a 3% CAGR Through 2034 | DelveInsight

Colorectal Cancer Market Poised for Steady Growth with a CAGR of 5% through 2034 | DelveInsight

Key Colorectal Cancer companies in the market include – Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Genentech, Merck, Takeda, Seagen Inc, Amgen, Pfizer, Roche, Genentech, GenFleet Therapeutics, InventisBio, BioNTec, and AbbVie, among others.

The Colorectal Cancer market size is experiencing substantial growth across the 7MM. This growth is primarily driven by an aging population, the introduction of innovative therapies, such as KRAS and HER2 inhibitors, improved screening methods, and changes in dietary habits. Key companies, including Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Genentech, Merck, Takeda, Seagen Inc, Amgen, Pfizer, Roche, Genentech, GenFleet Therapeutics, InventisBio, BioNTec, and AbbVie, among others are driving innovations in treatment approaches, addressing unmet needs inthe colorectal cancer landscape.

According to the latest insights from DelveInsight’s comprehensive report, ”Colorectal Cancer Market Insight, Epidemiology And Market Forecast – 2034”, the Colorectal Cancer market reached USD 13 billion across the 7MM in 2023, with projections indicating a steady CAGR of approximately 5% through 2034. This growth trajectory is supported by demographic shifts, including an aging population, changing dietary habits, and the introduction of innovative therapies, such as KRAS and HER2 inhibitors, alongside a deeper understanding of tumor biology and biomarker-driven treatment strategies.

The United States continues to dominate the Colorectal Cancer treatment market, accounting for approximately 40% of the total market share among 7MM in 2023. This is due to high adoption rates of premium-priced therapies, robust healthcare infrastructure, and favorable reimbursement frameworks.

Download the Colorectal Cancer market report to understand which factors are driving the Colorectal Cancer therapeutic market @ Colorectal Cancer Market Trends

The report also analyzes historical and projected Colorectal Cancer epidemiology, segmented by total colorectal cancer incident cases, gender-specific cases, age-specific cases, tumor localization-specific cases, stage-specific cases, mutation-specific cases, and the total treated colorectal cancer cases in the 7MM.

Colorectal Cancer remains a significant global health concern, ranking as the third most commonly diagnosed cancer worldwide. In 2024, the incident cases of mCRC were approximately 294,500 cases in the 7MM. The Colorectal Cancer epidemiological data reveal that the United States accounted for approximately 30% of the total incident cases among 7MM in 2023.

DelveInsight’s analysis further indicates that nearly 40% of the total incident cases of colorectal cancer in the US were classified as metastatic colorectal cancer, highlighting the urgent need for advanced treatment options for patients with late-stage disease. Additionally, age-specific data reveals a pronounced burden among individuals aged 65–84 years, emphasizing the correlation between aging populations and CRC incidence. Stage-specific distribution shows that localized colorectal cancer accounts for the highest proportion of cases, followed by regional, distant, and unknown stages, according to SEER data.

Moreover, the CRC Treatment Market Report provides insights into current treatment practices, emerging drugs, and the market share of individual colorectal cancer therapies. The current treatment landscape for colorectal cancer is characterized by a dynamic integration of traditional therapies, targeted treatments, and immunotherapy, reflecting significant advancements in precision oncology and molecular profiling.

Several targeted therapies, such as KRAZATI (Mirati Therapeutics), ENHERTU (AstraZeneca and Daiichi Sankyo), TUKYSA (Genentech/Seagen), KEYTRUDA (Merck), and FRUZAQLA (Takeda), among others, have revolutionized the CRC treatment market. While fluoropyrimidine-based chemotherapy regimens combined with biological agents like AVASTIN (bevacizumab) or ERBITUX (cetuximab) have long been standard options, there has been a recent shift toward biomarker-driven therapies targeting specific genetic alterations, such as KRAS, BRAF, and HER2 mutations.

Discover evolving trends in the Colorectal Cancer treatment landscape @ Colorectal Cancer Therapeutics Market.

Recently, in January 2025, the FDA approved sotorasib (Amgen) in combination with panitumumab for KRAS G12C-mutated colorectal cancer. In December 2024, the FDA granted accelerated approval to BRAFTOVI (Pfizer) in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF mutation. Pfizer is currently seeking full approval based on the Phase III BREAKWATER Trial.

DelveInsight’s analysis also indicates that the CRC therapeutic pipeline is rapidly evolving, driven by precision oncology and advancements in immunotherapy. Notable candidates, among others, include Divarasib (Roche/Genentech), GFH925 (GenFleet Therapeutics), D-1553 (InventisBio), Autogene cevumeran (BioNTech/Genentech), Onvansertib (Cardiff Oncology) and Telisotuzumab adizutecan (AbbVie), which targets the c-Met protein expressed in CRC cells along with a chemotherapy payload, a topoisomerase I inhibitor that kills cancer cells.

Recently, a phase 1 trial involving the immunotherapy drugs botensilimab and balstilimab has demonstrated remarkable promise for patients with microsatellite stable metastatic colorectal cancer (MSS mCRC), the most common form of colorectal cancer.

Another significant immunotherapy breakthrough involves JEMPERLI (GSK), which received FDA breakthrough therapy designation for locally advanced mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer in December 2024.

Unlock which Colorectal Cancer drug is expected to capture the largest market share in 7MM by 2032. Visit the Colorectal Cancer Market Insights

As the Colorectal Cancer market continues to evolve, key trends include the rise of targeted therapies, particularly KRAS inhibitors for specific mutations, advancements in immunotherapy, and an increased focus on personalized medicine approaches that tailor treatments to individual patient profiles. The role of early detection methods in shifting treatment paradigms and improving outcomes remains central to addressing this significant public health challenge.

Table of Contents

1	Key Insights
2	Report Introduction
3	Executive Summary of Colorectal Cancer
4	Key Events
5	Colorectal Cancer Epidemiology and Market Forecast Methodology
6	Colorectal Cancer Market Overview at a Glance
7	Disease Background and Overview: Colorectal Cancer
8	Colorectal Cancer Treatment and Management
9	Colorectal Cancer Epidemiology and Patient Populationin the 7MM
10	Colorectal Cancer Patient Journey
11	Key Endpoints in Colorectal Cancer
12	Colorectal Cancer Marketed Therapies
13	Colorectal Cancer Emerging Therapies
14	Colorectal Cancer: Seven Major Market Analysis
15	Colorectal Cancer Unmet Needs
16	SWOT Analysis
17	KOL Views
18	Market Access and Reimbursement
19	Appendix
20	DelveInsight Capabilities
21	Disclaimer
22	About DelveInsight

Related Reports

Colorectal Cancer Pipeline Insight

Colorectal Cancer Pipeline Insight provides comprehensive insights about the Colorectal Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Colorectal Cancer companies, including Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., and BioNTech SE, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Market Poised for Steady Growth with a CAGR of 5% through 2034 | DelveInsight

Nonmelanoma Skin Cancer Market Poised for Significant Growth by 2034 as Novel Therapies Emerge | DelveInsight

The Nonmelanoma Skin Cancer companies in the market include – Sensus Healthcare, DUSA Pharmaceuticals Inc., Skin Analytics Limited, Pfizer, Bristol-Myers Squibb, Sirnaomics, AiViva BioPharma, and Exicure, among others.

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing disease prevalence, advancements in diagnostic techniques, and the introduction of novel treatment options. As research progresses, new therapies will likely address existing treatment gaps, enhancing patient care and market growth. Leading Nonmelanoma Skin Cancer companies actively advancing research in this landscape include Sensus Healthcare, DUSA Pharmaceuticals Inc., Skin Analytics Limited, Pfizer, Bristol-Myers Squibb, Sirnaomics, AiViva BioPharma, and Exicure, among others.

DelveInsight’s “Nonmelanoma Skin Cancer Market Insight, Epidemiology, and Market Forecast – 2034” report delivers comprehensive insights into the rapidly evolving Nonmelanoma Skin Cancer treatment market across 7MM. The Nonmelanoma Skin Cancer market is projected to experience substantial growth during the 2024-2034 forecast period, driven by increasing disease prevalence, enhanced diagnostic capabilities, and the introduction of innovative treatment options. This growth trajectory reflects the expanding Nonmelanoma Skin Cancer patient pool and the robust development pipeline aimed at addressing significant unmet needs in this therapeutic area.

Download the Nonmelanoma Skin Cancer market report to understand which factors are driving the Nonmelanoma Skin Cancer therapeutic market @ Nonmelanoma Skin Cancer Market Trends

The Nonmelanoma Skin Cancer epidemiology landscape reveals that around 3.6 million cases of BCC and 2 million cases of SCC are diagnosed annually in the US. Moreover, the incidence of BCC was nearly equal between men and women, whereas SCC showed a slightly higher prevalence in women compared to men, suggesting a potential gender difference in the distribution of these skin cancers.

The report provides historical as well as forecasted Nonmelanoma Skin Cancer epidemiology segmented as Total Nonmelanoma Skin Cancer prevalent cases, Total diagnosed prevalent cases of Nonmelanoma Skin Cancer, Gender-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, Age-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, Region-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, and Treatable cases of Nonmelanoma Skin Cancer in the 7MM.

The report also discusses the current and emerging treatment of nonmelanoma skin cancer. The treatment market continues to evolve beyond conventional surgical approaches, which remain primary interventions. Current treatment options include topical therapies like imiquimod and 5-fluorouracil, photodynamic therapy, radiotherapy, and electrochemotherapy for certain cases. For advanced or metastatic disease, systemic chemotherapy utilizing drugs such as cisplatin and paclitaxel may be employed, with immunotherapy agents increasingly demonstrating efficacy in this patient population.

The current Nonmelanoma Skin Cancer treatment market features several established therapies that have reshaped patient care. VISMODEGIB (Erivedge), developed by Genentech, stands as the first FDA-approved pharmacologic agent targeting the Hedgehog signaling pathway for basal cell carcinoma patients who aren’t candidates for surgery or radiation. Complementing this approach, Sanofi’s LIBTAYO (cemiplimab-rwlc) gained FDA approval in September 2021 as the first immunotherapy for advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor.

The Nonmelanoma Skin Cancer therapeutics market also includes ODOMZO (Sun Pharma) and KEYTRUDA (Merck & Co), among others. KEYTRUDA (Merck & Co) received FDA approval for patients with recurrent or metastatic cutaneous squamous cell carcinoma not amenable to surgery or radiation.

Discover evolving trends in the Nonmelanoma Skin Cancer treatment landscape @ Nonmelanoma Skin Cancer Therapeutics Market

Additionally, AiViva BioPharma’s AIV001 recently received FDA clearance in December 2024 for intradermal injection testing facial skin for nonmelanoma skin cancer, specifically basal cell carcinoma. Another investigational drug, RP1 (Replimune Group), received the FDA Breakthrough Therapy designation in November 2024.

Among the most promising emerging therapies, Sirnaomics’ STP705 represents an innovative siRNA therapeutic leveraging proprietary dual-targeted inhibitory properties. Currently in Phase II trials for both basal cell carcinoma and cutaneous squamous cell carcinoma, this therapy exemplifies the scientific advancement characterizing the Nonmelanoma Skin Cancer drug market.

The Nonmelanoma Skin Cancer pipeline features several novel therapeutic approaches poised to impact the treatment paradigm significantly. Leading Nonmelanoma Skin Cancer companies actively advancing research include Sensus Healthcare, DUSA Pharmaceuticals Inc., Skin Analytics Limited, Pfizer, Bristol-Myers Squibb, Sirnaomics, AiViva BioPharma, and Exicure, among others. These industry leaders are driving innovation across the Nonmelanoma Skin Cancer treatment landscape, with several promising candidates progressing through clinical development.

Recently, according to the results published in April 2025, Silmitasertib (Senhwa Biosciences), which is being explored for patients who have relapsed after standard therapies, including hedgehog pathway and PD-1 inhibitors, showed progression-free survival exceeding 21 months in several patients in a Phase 1 dose-expansion trial for advanced BCC. Another study published in January 2025 demonstrated a 97% calculated objective response rate for VP-315 (Verrica Pharmaceuticals) in Part 2 of a Phase 2 study.

Unlock which Nonmelanoma Skin Cancer drug is expected to capture the largest market share in 7MM by 2032. Visit the Nonmelanoma Skin Cancer Market Insights

Despite the positive growth outlook, the Nonmelanoma Skin Cancer market faces challenges, including side effects for treatments such as radiation therapy and chemotherapy, pricing concerns, a lack of awareness about the disease among patients and healthcare providers, late diagnosis, reimbursement issues, and healthcare specialist shortages. Nevertheless, the forecasted period will likely witness transformative advances as emerging therapies address existing treatment gaps and expand therapeutic options for the substantial Nonmelanoma Skin Cancer patient population.

Table of Contents

1.	Key insights
2.	Executive Summary of Nonmelanoma Skin Cancer
3.	Nonmelanoma Skin Cancer: Market Overview at a Glance
4.	Disease Background and Overview: Nonmelanoma Skin Cancer
5.	Nonmelanoma Skin Cancer Treatment & Medical Practices
6.	Nonmelanoma Skin Cancer Patient Journey
7.	Nonmelanoma Skin Cancer Epidemiology and Patient Population
8.	NMSC: Country-Wise Epidemiology
9.	Nonmelanoma Skin Cancer Marketed Products
10.	Nonmelanoma Skin Cancer Emerging Therapies
11.	Nonmelanoma Skin Cancer Pipeline Profiles
12.	Nonmelanoma Skin Cancer: Market Size of NMSC
13.	7MM NMSC: Country-Wise Market Analysis
14.	SWOT Analysis
15.	KOL Views
16.	Nonmelanoma Skin Cancer Reimbursement and Market Access
17.	Appendix
18.	DelveInsight Capabilities
19.	Disclaimer
20.	About DelveInsight

Nonmelanoma Skin Cancer Pipeline Insight provides comprehensive insights about the Nonmelanoma Skin Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Nonmelanoma Skin Cancer companies, including Sensus Healthcare, DUSA Pharmaceuticals Inc., Skin Analytics Limited, Pfizer, Bristol-Myers Squibb, Sirnaomics, AiViva BioPharma, and Exicure, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nonmelanoma Skin Cancer Market Poised for Significant Growth by 2034 as Novel Therapies Emerge | DelveInsight

Indonesia Data Center Market Investment to Reach $3.79 Billion by 2030 – Arizton

“Indonesia Data Center Market Research Report by Arizton”

According to Arizton’s latest research report, Indonesia data center market is growing at a CAGR of 7.99% during 2024-2030.

To Know More, Click: https://www.arizton.com/market-reports/indonesia-data-center-market-analysis-2025

Report Summary     

Market Size – Investment (2030): $3.79 Billion     

Market Size – Area (2030): 570 Thousand Sq. ft.   

Market Size – Power Capacity (2030): 119 MW    

CAGR – Investment (2024-2030): 7.99%      

Colocation Market Size (2030): $1.15 Billion 

Historic Year: 2021-2023     

Base Year: 2024     

Forecast Year: 2025-2030     

Indonesia Emerging Data Center Market

Indonesia is rapidly becoming a key player in the APAC region for data center development, driven by factors such as increasing digitalization, government initiatives, and strong internet penetration. The country benefits from robust inland and submarine cable connectivity, with more than 50 existing submarine cables connecting Indonesia to global markets. These include key cables like the Australia-Singapore cable and SeaMeWe-5. Upcoming cables, such as Apricot and Bifrost, are further enhancing Indonesia’s connectivity.

The country’s data protection framework, governed by the Personal Data Protection (PDP) Law 2022, ensures safe data usage and protects users from fraud and breaches. Indonesia’s extensive network of submarine cables, such as the JaKa2LaDeMa cable, plays a significant role in boosting internal connectivity.

Additionally, the government has launched initiatives like the National Strategy for Artificial Intelligence (2020-2045) and the One Indonesia Data policy to accelerate digital transformation. With the increasing integration of 5G technology, Indonesia is seeing a surge in data generation and storage needs, prompting cloud service providers to invest in the establishment of new data centers in the country. This growing demand for data infrastructure highlights Indonesia’s position as an emerging data center hub in the APAC region.

Growth of the Data Center Market in Indonesia: Opportunities and Trends

Indonesia’s data center market is experiencing steady growth, with around 81 existing colocation facilities spread across key cities like Jakarta, Batam, and others. The increasing shift towards digital activities in the country has led to a rising demand for colocation services, creating significant opportunities for the sector. New market entrants like SM+, Digital Realty Bersama, Equinix, and Edge Centres are intensifying competition in the space.

The absorption rate of data centers in Indonesia is approximately 75%, with Jakarta seeing higher demand than other cities. The potential for oversupply exists, particularly depending on the demand from hyperscale cloud providers and internet service providers. Batam, benefiting from the spillover demand from Singapore, is emerging as a key location for data centers, especially after the lifting of Singapore’s moratorium on new data centers in 2022.

The sectors driving colocation demand include finance, telecom, healthcare, education, e-commerce, and social media, with large enterprises and government agencies increasingly migrating to cloud infrastructure. The government’s digitalization efforts, strong infrastructure, and adoption of renewable energy are expected to further boost the growth of Indonesia’s data center market.

Growing Investments in Batam, Indonesia: A Data Center Hub

Batam, strategically located near Singapore, is rapidly emerging as a key hub for data center development in Indonesia. This growth is supported by Indonesia’s “Making Indonesia 4.0” plan, which aims to digitize various industries, and the government’s creation of the Batam Free Trade Port Area and Special Economic Zone (SEZ) to attract investment. The Batam Industrial Development Authority (BIDA) facilitates these efforts by supporting economic growth in the region.

Batam’s location outside the earthquake and tsunami-prone “Ring of Fire” provides a significant advantage for data center operations. The Nongsa Digital Park (NDP), established in 2018, has become a preferred destination for data center operators due to its tech-friendly infrastructure, independent power stations, and high-speed broadband connectivity.

Additionally, Batam benefits from several existing submarine cables, with upcoming cables like Apricot, Asia Connect Cable-1, and Hawaiki Nui enhancing connectivity. This makes Batam an increasingly attractive destination for data center investments.

Why You Should Buy this Research?

This research offers an in-depth analysis of Indonesia’s data center market, providing valuable insights for investors and industry stakeholders. It covers key metrics such as market size, investment in colocation, hyperscale, and enterprise operators, and the power capacity of data centers across the country. The report details the existing and upcoming data centers in 18+ cities, including 81 facilities in operation and 24 planned, alongside forecasts for IT load capacity and area (thousand square feet).

Additionally, the study includes a detailed forecast for the colocation market from 2024 to 2030, highlighting trends in wholesale vs. retail colocation, pricing models, and investments in IT, power, cooling, and construction. The research also provides an analysis of growth opportunities, industry trends, and challenges, along with business overviews of major players in the sector. This comprehensive resource will aid in making informed strategic and investment decisions.

Buy this Research @ https://www.arizton.com/market-reports/indonesia-data-center-market-analysis-2025

The Report Includes the Investment in the Following Areas:

IT Infrastructure

Server Infrastructure
Storage Infrastructure
Network Infrastructure

Electrical Infrastructure

UPS Systems
Generators
Transfer Switches & Switchgears
PDUs
Other Electrical Infrastructure

Mechanical Infrastructure

Cooling Systems
Rack
Other Mechanical Infrastructure

Cooling Systems

CRAC and CRAH Units
Chillers Units
Cooling Towers, Condensers and Dry Coolers
Other Cooling Units

General Construction

Core & Shell Development
Installation & Commissioning Services
Building & Engineering Design
Fire Detection & Suppression Systems
Physical Security
Data Center Infrastructure Management (DCIM)

Tier Standard

Tier I & Tier II
Tier III
Tier IV

Geography

Jakarta
Batam

Vendor Landscape

IT Infrastructure Providers

Cisco Systems
Dell Technologies
Fujitsu
Hewlett Packard Enterprise
Hitachi Vantara
Huawei Technologies
IBM
Inspur
Lenovo

Data Center Construction Contractors & Sub-Contractors

Aesler Group
AO Construction
ARKONIN
Asdi Swasatya
Aurecon Group
Beca
Cundall
BW Design Group
DSCO Group
Leighton Asia
NTT Facilities
Obayashi Corporation
Parker van den Bergh
PT PP
Ramboll
PT SMI
Tetra
Turner & Townsend
Vale Architects
WT Asia

Support Infrastructure Providers

ABB
Caterpillar
Cummins
Cyber Power Systems
Delta Electronics
Eaton
Fuji Electric
HITEC Power Protection
Legrand
Mitsubishi Electric
Piller Power Systems
Rittal
Rolls-Royce
Schneider Electric
STULZ
Vertiv

Data Center Investors

BDx Data Centers
Biznet Data Center
Bitera Data Center
Datacomm Diangraha
DCI Indonesia
DTP Telecom
Elitery
EDGE DC
EdgeConneX
IndoKeppel Data Centres
IDC Indonesia
MettaDC
NTT DATA
Princeton Digital Group
Pure Data Centres
ST Telemedia Global Data Centres
Telkom Indonesia (NeutraDC)

New Entrants

BW Digital
DayOne
Digital Realty Bersama
EDGNEX Data Centres by DAMAC
Equinix
Evolution Data Centres
Gaw Capital
K2 Data Centres
Microsoft
Minoro Energi
SM+
SEAX Global
Singtel (Nxera)

Key Questions Answered in the Report:     

How big is the Indonesia data center market?

How much MW of power capacity will be added across Indonesia during 2025-2030?

What is the growth rate of the Indonesia data center market?

Which cities are included in the Indonesia data center market report?

What factors are driving the Indonesia data center market?

Check Out Some of the Top Selling Reports of Your Interest:     

Japan Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/japan-data-center-market-investment-analysis

Malaysia Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis

Why Arizton?     

100% Customer Satisfaction     

24×7 availability – we are always there when you need us     

200+ Fortune 500 Companies trust Arizton’s report     

80% of our reports are exclusive and first in the industry     

100% more data and analysis      

1500+ reports published till date     

Post-Purchase Benefit     

1hr of free analyst discussion     
10% off on customization

About Us:     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.  

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/indonesia-data-center-market-analysis-2025

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Indonesia Data Center Market Investment to Reach $3.79 Billion by 2030 – Arizton

Surge in Cyber Threats Accelerates Demand for Account Takeover Prevention in Banking Market – Industry Revenue is Set to Surge by $1.60 Billion by 2030 – Arizton

“ATO Prevention in Banking Market Research Report by Arizton”

According to Arizton’s latest research report, account takeover prevention in banking market is growing at a CAGR of 9.01% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/account-takeover-prevention-in-banking-market

Report Scope:           

Market Size (2030): $1.60 Billion     

Market Size (2024): $935.98 Million     

CAGR (2024-2030): 9.01%     

Historic Year: 2021-2023     

Base Year: 2024     

Forecast Year: 2025-2030     

Market Segmentation: Service Type, Development Type, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa     

Account Takeover (ATO) fraud is a major threat in online banking, where cybercriminals gain access through stolen credentials, phishing, or malware. To combat this, banks invest in advanced ATO prevention technologies while balancing security with user experience. Measures like Multi-Factor Authentication (MFA) and CAPTCHA reduce fraud but can create customer friction. AI-based behavioral authentication and risk-based security are employed to mitigate these challenges, while fintech platforms and digital wallets increase the attack surface. Banks use AI-powered fraud detection to monitor login habits, transaction patterns, and biometrics, with behavioral biometrics like keystroke dynamics helping identify fraudulent activities.

The ATO prevention market in banking is rapidly growing due to increased electronic transactions and more sophisticated hackers. Traditional password-based security is ineffective against phishing and credential stuffing, prompting banks to adopt FIDO2-based authentication, biometric methods, and passwordless solutions. Risk-based authentication (RBA) ensures minimal inconvenience for genuine users while blocking attackers. Dark web monitoring tools help detect compromised credentials, while liveness detection and AI-driven identity verification counter deepfakes and synthetic identities. Rising consumer awareness of cyber threats like ATO fraud, driven by data breaches and phishing attacks, is pushing banks to invest in advanced fraud prevention solutions that balance security and user experience.

Recent Vendor Activities

On September 12, 2024, Mastercard announced an agreement to acquire global threat intelligence company Recorded Future from Insight Partners for $2.65 billion. This acquisition enhances Mastercard’s cybersecurity capabilities, strengthening the insights and intelligence used to protect the digital economy, including the payments ecosystem and beyond.
On December 4, 2023, Thales announced the successful completion of its acquisition of Imperva. This transaction is expected to create substantial value for Thales’ shareholders.

Pre-Transaction Service Type Gaining Momentum

Pre-transaction prevention measures are essential for blocking ATO fraud before transactions occur, using technologies like MFA, RBA, identity verification, device fingerprinting, and PAM. ATO attacks have surged due to data breaches and credential stuffing, with cybercriminals using stolen credentials from the dark web to target accounts. Banks are adopting AI-powered solutions like MFA, behavioral biometrics, and RBA to thwart automated bot-based attacks and ensure secure login. Cloud-based fraud detection allows real-time monitoring of transactions. Regulatory frameworks such as PSD2, CCPA, and FFIEC require strong customer authentication, driving demand for AI-driven identity verification and biometric authentication in the banking sector.

Competitive Landscape and Future Trends in ATO Prevention for Banking

The ATO prevention market in banking is highly competitive, with vendors differentiating themselves through technological innovation, comprehensive offerings, and strategic partnerships. Established cybersecurity companies dominate the market, making it challenging for new entrants to stand out. Banks prefer long-term relationships with reputable suppliers, further hindering new competitors. The market is also at risk from low-cost, low-quality security solutions that fail to provide adequate fraud detection. Moving forward, the future of ATO prevention will focus on security-driven, friction-reducing, and accurate fraud detection technologies. This includes the shift away from passwords and OTPs toward behavioral biometrics, AI/ML, and frictionless authentication methods.

Looking for More Information? Click: https://www.arizton.com/market-reports/account-takeover-prevention-in-banking-market

Key Vendors

Datavisor
Entrust
Experian
Kount
LexisNexis Risk Solutions
Ping Identity
Accertify
Arkose Labs
BioCatch
Bureau
Combate a Fraude (Caf)
Callsign
Entersekt
Feedzai
Human
Imperva
Mastercard
Outseer
Prove Identity
Socure
SpyCloud
Telesign
Transmit Security
TransUnion

Segmentation & Forecasts

Service Type

Pre-Transaction
During-Transaction
Post-Transaction

Deployment Type

Cloud-Based
On-Premise

Geography

North America

US
Canada

Europe

UK
Germany
France
Italy

APAC

China
India
Australia
Japan

Latin America

Brazil
Mexico

Middle East & Africa

Turkey
Saudi Arabia

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the ATO prevention in banking market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/account-takeover-prevention-in-banking-market

What Key Findings Will Our Research Analysis Reveal?         

What is the expected growth of the global ATO prevention in banking market?

What is the growth rate of the global ATO prevention in banking market?

What are the factors driving global ATO prevention in banking market growth?

Which region will have the highest CAGR in the global ATO prevention in banking market?

Who are the major players in the global ATO prevention in banking market?

Other Related Reports that Might be of Your Business Requirement     

Generative AI in Software Development Market – Global Outlook & Forecast 2025 – 2030

https://www.arizton.com/market-reports/generative-ai-in-software-development-market

Financial Wellness Benefits Market in the United States – Research Report 2020-2029

https://www.arizton.com/market-reports/financial-wellness-benefits-market-in-united-states

Why Arizton?    

100% Customer Satisfaction

24×7 availability – we are always there when you need us

200+ Fortune 500 Companies trust Arizton’s report

80% of our reports are exclusive and first in the industry

100% more data and analysis

1500+ reports published till date

Post-Purchase Benefit                                                

1hr of free analyst discussion
10% off on customization

About Us:                                                                                         

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surge in Cyber Threats Accelerates Demand for Account Takeover Prevention in Banking Market – Industry Revenue is Set to Surge by $1.60 Billion by 2030 – Arizton

Pet Tech Industry Report 2024-2030: Global Market Projected to Reach $17.25 Billion in the Next 6 Years – Exclusive Research Insights by Arizton

“Pet Tech Market Research Report by Arizton”

According to Arizton’s latest research report, pet tech market is growing at a CAGR of 14.56% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/pet-tech-market

Report Scope:          

Market Size (2030): $17.25 Billion    

Market Size (2024): $7.63 Billion    

CAGR (2024-2030): 14.56%    

Historic Year: 2021-2023    

Base Year: 2024    

Forecast Year: 2025-2030    

Market Segmentation: Product, Technology, Distribution Channel, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa    

The pet tech industry is expected to continue its double-digit growth over the next decade, with increasing investments in AI-powered health diagnostics and connected pet ecosystems. As consumer demand for convenience and personalized solutions grows, the market will see further consolidation through mergers, acquisitions, and strategic collaborations. Companies focusing on innovation, data security, and integration within the pet care ecosystem will gain a competitive edge in this rapidly evolving market. Leading players like Whistle & FitBark, Tractive, and Garmin dominate the pet wearable segment, offering GPS trackers and health-monitoring devices, while Petcube and Furbo are prominent in pet monitoring with interactive cameras. Additionally, smart solutions for feeding and waste management, such as Litter-Robot, Sure Petcare, and PetSafe, are rapidly growing in popularity.

Innovation plays a critical role in this market, with AI, IoT, and machine learning being integrated into products to enhance tracking, health diagnostics, and pet behavior insights. The integration of 5G and IoT connectivity is expected to accelerate advancements, enabling seamless real-time tracking and interaction. Sustainability is also a focus, with eco-friendly products like automated litter boxes and AI-powered feeders evolving with self-cleaning and monitoring features. North America and Europe currently lead the market, driven by high pet ownership rates and strong consumer demand for smart pet products, while Asia-Pacific, particularly China, Japan, and South Korea, is seeing rapid growth. Latin America and the Middle East are emerging markets, where affordability remains a challenge, but rising pet adoption is fueling the market demand.

Monitoring Devices to Contribute Largest Share in the Pet Tech Market

Pet owners often worry about the well-being of their pets when they are away from home, but recent technological advancements have introduced innovative solutions to provide reassurance. Pet monitoring systems, including specialized cameras and security devices, enable real-time tracking of pets’ health, behavior, and safety. These devices offer valuable insights that ensure pets remain safe and well-cared for, reducing owners’ anxieties.

Pet cameras, such as those offered by Furbo, WOPET, Petcube, and Enabot, are designed to allow remote monitoring and interaction with pets. These cameras typically feature live video streaming, two-way audio, treat dispensers, and built-in games to keep pets engaged. Some models also offer additional features like pet activity alerts and remote interactions, which help reduce pet loneliness and improve their well-being while owners are away.

In 2024, new models like the Xiaomi 360 Home Security Camera and Honor Xiaopai Smart Camera Pro have been introduced, with advanced features such as AI detection, 360-degree coverage, night vision, and cloud storage integration. These cameras are designed not only for pet monitoring but also for home security, making them valuable tools for both pet owners and small businesses like pet daycare centers and grooming salons.

Overall, the growing popularity of smart pet cameras reflects the increasing demand for pet safety and interaction, providing peace of mind to owners and ensuring their pets’ safety and engagement when they are not around.

Global Pet Tech Market Latest News & Developments

In March 2025, Enabot launched the EBO Air 2, a smart home robot that enhances security and pet interaction with a 2K Ultra HD camera, 360° mobility, night vision, and AI-powered features. Offering motion detection, two-way talk, and customizable expressions, it keeps homes monitored and pets entertained. The EBO Air 2 strengthens Enabot’s position in the growing pet tech market, appealing to security-conscious homeowners and pet owners seeking interactive, AI-driven solutions. Its innovation boosts brand recognition and market competitiveness.
In January 2025, Satellai partnered with Qualcomm to revolutionize pet tracking with the Satellai Tracker, integrating Qualcomm’s advanced chipset technology. This collaboration enhances Satellai’s market position by offering cutting-edge, reliable tracking, even in no-signal areas, boosting pet safety and customer trust.
In January 2025Tractive named Sandrine Arcizet as its Brand Ambassador for France, leveraging her influence to promote its GPS and health trackers. The new DOG 6 tracker introduces Bark Monitoring, with future heart and respiratory rate tracking for enhanced pet safety. This partnership boosts Tractive’s visibility, educating pet owners and reinforcing its market leadership in data-driven pet tech.

The Role of Online Distribution in the Growth of the Pet Tech Industry

The pet tech industry has experienced substantial growth, fueled by the rising demand for smart pet products, health monitoring devices, and automated pet care solutions. Online distribution channels have played a pivotal role in this expansion, allowing pet tech companies to reach a global audience with ease. E-commerce platforms, direct-to-consumer (DTC) websites, online marketplaces, subscription services, and digital partnerships with veterinary networks and pet retailers are essential tools for enhancing accessibility, customer engagement, and sales.

Online retailers such as Amazon, Chewy, and Petco offer extensive selections of pet products, making it easier for consumers to find and purchase smart pet solutions. These platforms utilize search algorithms, product reviews, and targeted advertising to help brands connect with pet owners. Specialized pet-focused marketplaces like Petco and PetSmart’s online stores further support niche pet care innovations.

Many pet tech brands adopt a DTC approach through their websites, allowing full control over pricing, branding, and customer relationships. This model facilitates the collection of first-party data to create personalized marketing campaigns and loyalty programs. Additionally, subscription services for consumables like smart pet feeders and GPS tracker services generate recurring revenue and foster long-term customer loyalty.

Social media platforms, particularly Instagram, Facebook, and TikTok, have become crucial distribution channels for pet tech brands. Influencer partnerships, user-generated content, and features like direct shopping on these platforms enable brands to reach target demographics efficiently, improving brand awareness and customer acquisition.

Moreover, partnerships with veterinary clinics, online pet pharmacies, and pet health platforms help integrate pet tech products into wellness programs, enhancing their credibility. Bundling smart pet devices with insurance plans or veterinary services via digital channels further boosts customer adoption and trust, cementing the role of online distribution in the pet tech industry’s continued growth.

Looking for More Information? Click: https://www.arizton.com/market-reports/pet-tech-market

Pet Tech Market Key Company Profiles

Garmin Ltd
Mars, Incorporated
Pawbo
Petcube
Actijoy
Aimicat
Casa Leo
Cheerble
Dogtra
E-Collar Technologies, Inc.
ELECOM CO., LTD.
Enabot
Felcana
Furbo
iKuddle
Invoxia
Kippy
MiniFinder
Moggie
PerpetualWell
PET MARVEL
Petbiz
PETBLE
PETKIT
Petlibro, Inc
PetPace
PetSafe Brands
PupPod
SATELLAI
Sure Petcare
Tractive
Wayzn
WOPET
Xiaomi
Zhejiang Dingyuan Pet Products Co., Ltd.

Market Segmentation

Product

Monitoring Devices
Tracking Devices
Entertainment Devices
Others

Technology

RFID
GPS
Sensors

Distribution Channel

Offline
Online

Geography

North America

The U.S.
Canada

Europe

The U.K.
France
Germany
Italy
Spain
Netherlands
Poland
Belgium

APAC

China
Japan
India
Philippines
South Korea
Australia

Middle East & Africa

UAE
Saudi Arabia
South Africa

Latin America

Brazil
Mexico
Argentina

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the pet tech market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/pet-tech-market

What Key Findings Will Our Research Analysis Reveal?        

How big is the global pet tech market?

What is the growth rate of the global pet tech market?

Who are the key players in the global pet tech market?

What are the significant trends in the pet tech market?

Which region dominates the global pet tech market share?

Other Related Reports that Might be of Your Business Requirement    

Global Pet Food Market – Focused Insights 2025-2030

https://www.arizton.com/market-reports/pet-food-market

U.S. Pet Grooming and Boarding Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-pet-grooming-and-boarding-market

Why Arizton?   

100% Customer Satisfaction                                                   

24×7 availability – we are always there when you need us                                                   

200+ Fortune 500 Companies trust Arizton’s report                                                   

80% of our reports are exclusive and first in the industry                                                   

100% more data and analysis                                                   

1500+ reports published till date                                 

Post-Purchase Benefit                                               

1hr of free analyst discussion                                               
10% off on customization

About Us:                                                                                        

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pet Tech Industry Report 2024-2030: Global Market Projected to Reach $17.25 Billion in the Next 6 Years – Exclusive Research Insights by Arizton

Colombia Data Center Market Investment to Hit $1.16 Billion by 2030 – Arizton

“Colombia Data Center Market Research Report by Arizton”

According to Arizton’s latest research report, Colombia data center market is growing at a CAGR of 17.55% during 2024-2030.

To Know More, Click: https://www.arizton.com/market-reports/colombia-data-center-market

Report Summary      

Market Size – Investment (2030): $1.16 Billion      

Market Size – Area (2030): 201 Thousand Sq. ft.    

Market Size – Power Capacity (2030): 47 MW     

CAGR – Investment (2024-2030): 17.55%       

Colocation Market Size – Revenue (2030): $280 Million

Historic Year: 2021-2023      

Base Year: 2024      

Forecast Year: 2025-2030      

Market Opportunities

Colombia is making significant strides in enhancing its submarine cable infrastructure, which is crucial for boosting its data center market and improving regional connectivity. The ongoing expansion of submarine cables is transforming Colombia into a strategic hub for global data flow and digital services in Latin America. These cables increase international bandwidth and reduce latency, positioning Colombia as a key player in the region’s digital economy.

As of 2024, Colombia is home to around ten operational submarine cables, with three more expected to go online in the near future. The MANTA submarine cable, a 3,480-mile system, is scheduled to be operational by 2027 and will connect Colombia, Mexico, Panama, and the US. Another significant project, the 4,350-mile TAM-1 cable, is expected to be ready by 2025, linking several countries including Colombia, Costa Rica, Guatemala, Honduras, and the US.

Colombia’s Expanding Data Center Colocation Market

Colombia’s data center colocation market is experiencing rapid growth, with around 23 operational facilities, primarily Tier III, concentrated in Bogota. Major colocation service providers in the country include ODATA (Aligned Data Centers), Equinix, DHAmericas, KIO Networks, Cirion Technologies, Claro, and HostDime, along with new entrants like Ascenty, Scala Data Centers, and EdgeConneX, all of which are either developing or planning new data center facilities.

In 2024, retail colocation made up approximately 68% of the market share, while wholesale colocation accounted for 32%. However, by 2030, wholesale colocation is expected to surpass 45%, with retail colocation contributing the remaining 55%. This shift is driven by the expansion of wholesale colocation operators such as Scala Data Centers and Ascenty, and the growth of existing players like ODATA.

Strategic partnerships are also enhancing market growth, with global cloud service providers, such as Amazon Web Services (AWS), renewing contracts with local enterprises like Claro to offer cloud solutions in Colombia. Leading retail colocation companies like Equinix, Claro, Cirion Technologies Gtd, Edge Uno, and HostDime are expected to maintain a stable revenue generation of around $2.5 million per MW throughout the forecast period. The market is poised for further expansion, driven by both local and international players capitalizing on the growing demand for cloud and colocation services.

Key Developments in Colombia Data Center Market

Colombia’s data center market is thriving with significant investments from both global and regional operators, including ODATA (Aligned Data Centers), Equinix, DHAmericas, KIO Networks, Claro, Tecto Data Centers (V.tal), Cirion Technologies, and HostDime, all contributing to the country’s growing digital infrastructure.

In October 2024, ODATA (Aligned Data Centers) announced a major investment of USD 1.3 billion to build two new data centers, BG02 and BG03, in Bogota, which are expected to begin operations by the end of 2026. DHAmericas, a key player in the market, opened its first data center facility in the Bogota Metropolitan Region within the secure Zona Franca Occidente (ZFO) economic free zone and is planning an additional five facilities in the coming years.

New entrants, such as Ascenty, EdgeConneX, and Scala Data Centers, are also expanding their footprint in the Colombian market, reflecting the country’s growing demand for data infrastructure. Additionally, Colombia’s cloud market is developing rapidly, with Oracle becoming the first company to open a public cloud region in the country in 2023, featuring one availability zone. These developments underline Colombia’s position as a key player in the regional data center and cloud market.

Why You Should Buy this Research?

This research provides a thorough analysis of the growing data center market in Colombia, focusing on critical investment areas, power capacity, and revenue potential in the colocation sector. It assesses data center investments across colocation, hyperscale, and enterprise operators, with detailed insights into the market size, square footage, and power capacity (MW) in various cities across Colombia. The study includes an in-depth examination of the existing data center landscape, offering valuable predictions on market growth during the forecast period.

Additionally, the research covers a snapshot of 23 existing and 12 upcoming data center facilities across 4+ locations, providing detailed comparisons between existing and upcoming data center area and IT load capacity. It delves into the colocation market, with revenue and forecast analysis (2021-2030) and detailed pricing trends for both retail and wholesale colocation services. The report further classifies market investments into IT, power, cooling, and construction services, offering sizing and forecasts for each. A comprehensive analysis of industry trends, growth rates, opportunities, and potential challenges is also included, along with a review of key players in the market, including IT infrastructure providers, contractors, and investors. The research methodology is transparent, providing a clear understanding of both the demand and supply dynamics within Colombia’s data center market, making it an essential resource for investors and stakeholders looking to capitalize on this rapidly developing sector.

Existing Vs. Upcoming Data Centers

Existing Facilities in the Region (Area and Power Capacity)

Bogota
Other Cities

List of Upcoming Facilities in the Region (Area and Power Capacity)

Bogota
Other Cities

Buy this Research @ https://www.arizton.com/market-reports/colombia-data-center-market

The Report Includes the Investment in the Following Areas:

IT Infrastructure

Server Infrastructure
Storage Infrastructure
Network Infrastructure

Electrical Infrastructure

UPS Systems
Generators
Transfer Switches & Switchgears
PDUs
Other Electrical Infrastructure

Mechanical Infrastructure

Cooling Systems
Racks
Other Mechanical Infrastructure

Cooling Systems

CRAC and CRAH Units
Chillers Units
Cooling Towers, Condensers and Dry Coolers
Other Cooling Units

General Construction

Core & Shell Development
Installation & commissioning Services
Building & Engineering Design
Fire Detection & Suppression Systems
Physical Security
Data Center Infrastructure Management (DCIM)

Tier Standard

Tier I & Tier II
Tier III
Tier IV

VENDOR LANDSCAPE

IT Infrastructure Providers

Arista Networks
Broadcom
Cisco
Dell Technologies
Hewlett Packard Enterprise
Huawei Technologies
IBM
Lenovo
NetApp
Oracle
Pure Storage

Data Center Construction Contractors & Sub-Contractors

AECOM
Fluor Corporation
Quark
ZFB Group
Support Infrastructure Providers
ABB
Alfa Laval
Assa Abloy
Bosch Security & Safety Systems
Caterpillar
Cummins
Daikin Applied
Delta Electronics
Eaton
Generac Power Systems
Honeywell
Johnson Controls
Legrand
Mitsubishi Electric
Piller Power Systems
Panduit
Rittal
Schneider Electric
Siemens
STULZ
Vertiv

Data Center Investors

Claro
Cirion Technologies
Etix Everywhere
Edge Uno
Equinix
DHAmericas
GlobeNet International Corp.
Gtd Colombia
HostDime
IPXON Networks
KIO Networks
ODATA (Aligned Data Centers)
Tecto Data Centers (V.tal)

New Entrants

Ascenty
EdgeConneX
Scala Data Centers

Key Questions Answered in the Report:      

How big is the Colombia data center market?

How much MW of power capacity will be added across Colombia during 2024-2029?

What factors are driving the Colombia data center market?

What is the growth rate of the Colombia data center market?

Check Out Some of the Top Selling Reports of Your Interest:      

Mexico Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/mexico-data-center-market-investment-analysis

Latin America Data Center Market Landscape 2025-2030

https://www.arizton.com/market-reports/latin-america-data-center-market-analysis

Why Arizton?      

100% Customer Satisfaction      

24×7 availability – we are always there when you need us      

200+ Fortune 500 Companies trust Arizton’s report      

80% of our reports are exclusive and first in the industry      

100% more data and analysis       

1500+ reports published till date      

Post-Purchase Benefit      

1hr of free analyst discussion      
10% off on customization

About Us:      

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colombia Data Center Market Investment to Hit $1.16 Billion by 2030 – Arizton